Rituximab efficacy for minimal residual disease eradication in philadelphia-negative acute lymphoblastic leukemia CD20+
Rituximab has never been investigated in MRD persistence/relapse. We describe a clinical picture of a woman with Ph-negative B-ALL CD20<sup>+</sup>, ineligible to allogeneic transplant, achieving MRD eradication using rituximab monotherapy after frontline chemotherapy and blinatumomab failure. This demonstrates rituximab's potential in MRD<sup>+</sup> Ph-negative B-ALL CD20<sup>+</sup>, warranting further clinical investigation.
Authors
- Francesco Passamonti (ORCID: https://orcid.org/0000-0001-8068-5289)
- Nicola Fracchiolla (ORCID: https://orcid.org/0000-0002-8982-8079)
- Elena Tagliaferri
- Mariarita Sciumé (ORCID: https://orcid.org/0000-0001-7958-4966)
- Nicola Cecchi (ORCID: https://orcid.org/0000-0002-4605-2127)
- Alessandro Bosi (ORCID: https://orcid.org/0000-0002-7686-2171)
- Antony Ricchiuti
Institutions
- University of Milan (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
Publication Details
- Journal
- Annals of Hematology
- Published
- 2025-05-15
- DOI
- https://doi.org/10.1007/s00277-025-06332-y
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministero della Salute